NCT05976828View on ClinicalTrials.gov

IBRX-042 In Participants With HPV-Associated Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 14, 2024

Primary Completion Date

September 2, 2027

Study Completion Date

August 14, 2033

Conditions
HPV-Related Carcinoma
Interventions
DRUG

IBRX-042

"* Dose cohort 1: 1e11 virus particles (VP)/dose~* Dose cohort 2: 5e11 VP/dose~* If needed, dose cohort -1 (de-escalation): 5e10 VP/dose"

Trial Locations (3)

77030

The University of Texas - MD Anderson Cancer Center, Houston

78731

Texas Oncology Austin Central, Austin

90245

Chan Soon-Shiong Institute for Medicine (CSSIFM), El Segundo

Sponsors

Lead Sponsor

ImmunityBio, Inc.
All Listed Sponsors
lead

ImmunityBio, Inc.

INDUSTRY